Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma : secondary analysis of the phase 3 ENDEAVOR study

Goldschmidt, Hartmut; Moreau, Philippe; Ludwig, Heinz; Niesvizky, Ruben; Chng, Wee-Joo; Joshua, Douglas; Weisel, Katja; Spencer, Andrew; Orlowski, Robert Z.; Feng, Shibao; Iskander, Karim S.; Dimopoulos, Meletios A.

dc.contributor.author	Weisel, Katja
dc.date.accessioned	2020-01-28T09:43:58Z
dc.date.available	2020-01-28T09:43:58Z
dc.date.issued	2018
dc.identifier.issn	1029-2403
dc.identifier.uri	http://hdl.handle.net/10900/97429
dc.language.iso	en	de_DE
dc.publisher	Taylor & Francis Ltd	de_DE
dc.relation.uri	http://dx.doi.org/10.1080/10428194.2017.1376743	de_DE
dc.subject.ddc	610	de_DE
dc.title	Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma : secondary analysis of the phase 3 ENDEAVOR study	de_DE
dc.type	Article	de_DE
utue.quellen.id	20190321153956_04302
utue.publikation.seiten	1364-1374	de_DE
utue.personen.roh	Goldschmidt, Hartmut
utue.personen.roh	Moreau, Philippe
utue.personen.roh	Ludwig, Heinz
utue.personen.roh	Niesvizky, Ruben
utue.personen.roh	Chng, Wee-Joo
utue.personen.roh	Joshua, Douglas
utue.personen.roh	Weisel, Katja
utue.personen.roh	Spencer, Andrew
utue.personen.roh	Orlowski, Robert Z.
utue.personen.roh	Feng, Shibao
utue.personen.roh	Iskander, Karim S.
utue.personen.roh	Dimopoulos, Meletios A.
dcterms.isPartOf.ZSTitelID	Leukemia & Lymphoma	de_DE
dcterms.isPartOf.ZS-Issue	6	de_DE
dcterms.isPartOf.ZS-Volume	59	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE